 PLANO, Texas, March 01, 2021 GLOBE NEWSWIRE -- Reata Pharmaceuticals, Inc. Nasdaq: RETA Reata, the Company, or we, a clinical-stage biopharmaceutical company, today announced that it has submitted a New Drug Application NDA for bardoxolone methyl bardoxolone for the treatment of chronic kidney disease CKD caused by Alport syndrome to the U.S. Food and Drug Administration FDA. 